Study record managers: refer to the Data Element Definitions if submitting registration or results information.
|1||NCT01701076||Completed||Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma||
||Other / Industry||
||50||All||18 Years and older (Adult, Senior)||NCT01701076||CTU10.041/BRd
|BRd||March 2012||February 2016||February 2016||October 4, 2012||August 24, 2016||